Literature DB >> 10365850

An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19.

M Tsuji1, T Kashihara, N Terada, H Mori.   

Abstract

Eight hepatic atypical adenomatous hyperplasias (AH), 30 hepatocellular carcinomas (HCC) consisting of 11 well-, 13 moderately and six poorly differentiated HCC, and 10 intrahepatic cholangiocarcinomas (CC) were investigated immunohistochemically with anti-alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), CA19-9, epithelial membrane antigen (EMA), and cytokeratins (CK) 18 and 19 antibodies. Immunostaining was regarded as positive when more than 5% of cells were stained. Alpha-fetoprotein was positive, although focally, in five (17%) of 30 HCC but negative in all AH and CC. Carcinoembryonic antigen (polyclonal antibody) did not stain the cytoplasm of all AH and HCC, but stained two (25%) of eight AH and 10 (33%) of 30 HCC in a bile canalicular staining manner. Carcinoembryonic antigen showed intracytoplasmic or luminal border staining in six (60%) of 10 CC. CA19-9 was negative in all AH and HCC, while six (60%) of 10 CC were positive for CA19-9. Epithelial membrane antigen was positive in one (13%) of eight AH, seven (23%) of 30 HCC and in all 10 cases of CC. Cytokeratin 18 was positive in all AH, HCC and CC. Cytokeratin 19 was negative in both AH and HCC, whereas it stained the cytoplasm of tumor cells in all CC diffusely and intensely. These results suggest that immunostaining of AFP, CEA, CA19-9, EMA, CK18 and CK19 are not useful in the differential diagnosis between AH and well-differentiated HCC, and that CK19 is the most suitable reagent for the differential diagnosis between HCC and CC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10365850     DOI: 10.1046/j.1440-1827.1999.00865.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  22 in total

1.  Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.

Authors:  Xing-Lei Qin; Zhuo-Ren Wang; Jing-Sen Shi; Min Lu; Lin Wang; Quan-Ru He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

2.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

Review 3.  [Diagnosis and differential diagnosis of hepatocellular carcinoma].

Authors:  U Drebber; H P Dienes
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

4.  Tumor-specific marker genes for intrahepatic cholangiocarcinoma: utility and mechanistic insight.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  J Hepatol       Date:  2008-05-22       Impact factor: 25.083

5.  The Applicability of a Human Immunohistochemical Panel to Mouse Models of Hepatocellular Neoplasia.

Authors:  Kenneth J Salleng; Frank L Revetta; Natasha G Deane; M Kay Washington
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

6.  Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma.

Authors:  Jinyan Zhang; Tao Huang; Fan Zhang; Junming Xu; Guoqing Chen; Xiaoliang Wang; Li Huang; Zhihai Peng
Journal:  Tumour Biol       Date:  2015-03-19

7.  Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients.

Authors:  Liang-He Lu; Yong-Fa Zhang; Wei Wei; Ming Shi; Rong-Ping Guo
Journal:  J Gastrointest Surg       Date:  2017-08-24       Impact factor: 3.452

8.  Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report.

Authors:  K Tanaka; T Honna; Y Kitano; T Kuroda; K Tanaka; N Morikawa; H Matsuda; N Kawashima; K Matsuoka; J Miyauchi
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

9.  Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.

Authors:  Mitsumaro Itoyama; Masaki Hata; Koji Yamanegi; Naoko Yamada; Hideki Ohyama; Hiroshi Hirano; Nobuyuki Terada; Keiji Nakasho
Journal:  Med Mol Morphol       Date:  2012-03-20       Impact factor: 2.309

10.  Expression of hepatocyte markers in mass-forming peripheral and periductal-infiltrating hilar intrahepatic cholangiocarcinomas.

Authors:  Hiroya Iida; Masaki Hata; Ayako Kakuno; Hiroshi Hirano; Koji Yamanegi; Naoko Yamada; Hideki Ohyama; Nobuyuki Terada; Chiaki Yasui; Naoki Yamanaka; Keiji Nakasho
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.